Could a triple-drug combo before surgery beat standard care for cervical cancer?
NCT ID NCT07088731
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 31 times
Summary
This study compares two treatments for locally advanced cervical cancer: standard chemoradiotherapy versus a new approach using chemotherapy plus immunotherapy (sintilimab) before surgery. The goal is to see if the new combination improves how long patients live without their cancer getting worse. About 180 adults aged 18-70 with specific stages of cervical cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Gynecological Oncology
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.